LIDODERM®
This product information is intended for U.S. residents only.
LIDODERM (Lidocaine Patch 5%) is indicated for relief of pain associated with post-herpetic neuralgia (PHN). Apply only to intact skin.
PHN results from nerve damage caused by the varicella zoster virus that causes shingles. The condition causes sharp, burning localized pain that occurs in different areas of the body such as the torso, upper arms or on one side of the face. LIDODERM is applied directly to the painful areas (apply only to intact skin) to reduce pain without completely numbing the area.
LIDODERM is a prescription patch that offers a no-pill way to achieve relief of after-shingles pain (post-herpetic neuralgia).
LIDODERM is the only prescription patch approved by the U.S. Food and Drug Administration (FDA) to relieve after-shingles pain.
Visit
www.lidoderm.com to learn more
- Important Safety Information
- LIDODERM® (Lidocaine Patch 5%) is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.
- LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.
- Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects form chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important to store and dispose of LIDODERM out of the reach of children, pets, and others.
- Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in absorption of lidocaine and high blood concentrations leading to serious adverse effects.
- Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns.
- Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.
- Allergic reactions, although rare, can occur.
- During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache, and nausea.
- When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.
- Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.
- Please see the Full Prescribing Information for LIDODERM.
LIDODERM® is a registered trademark of Hind Health Care, Inc.
*By clicking on the link(s) on this page you will leave the Endo.com website and move to an external website(s) independently operated and not managed by Endo Pharmaceuticals. Because Endo Pharmaceuticals does not control the content of the website(s) you are about to visit, and due to its constantly changing nature, we cannot be responsible for its content, accuracy, practices, or standards.
